Community-Acquired Pneumonia Treatment Guidelines
Outpatient Treatment
- The Infectious Diseases Society of America recommends a macrolide (azithromycin, clarithromycin, or erythromycin) for previously healthy patients with community-acquired pneumonia (strong recommendation; level I evidence) 3
- For patients with comorbidities or risk factors for drug-resistant Streptococcus pneumoniae (DRSP), the Infectious Diseases Society of America recommends a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750mg) or a β-lactam plus a macrolide (strong recommendation; level I evidence) 3
- In regions with high rates (>25%) of macrolide-resistant S. pneumoniae, the Infectious Diseases Society of America suggests using alternative agents even in previously healthy patients (moderate recommendation; level III evidence) 3
Inpatient Treatment
- The Infectious Diseases Society of America recommends a respiratory fluoroquinolone alone or a β-lactam plus a macrolide for inpatient treatment of community-acquired pneumonia (strong recommendation; level I evidence) 5
- For patients with risk factors for gram-negative pathogens (excluding Pseudomonas), the Infectious Diseases Society of America suggests using ertapenem (level III evidence) 5
ICU Treatment
- The Infectious Diseases Society of America recommends a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus either azithromycin or a fluoroquinolone for standard ICU treatment of community-acquired pneumonia (level II evidence) 1
- When Pseudomonas is a concern, the Infectious Diseases Society of America recommends an antipneumococcal, antipseudomonal β-lactam plus either ciprofloxacin or levofloxacin, or an aminoglycoside plus azithromycin or an antipneumococcal fluoroquinolone (level I evidence) 5
Timing and Duration of Therapy
- The Infectious Diseases Society of America recommends administering the first antibiotic dose while still in the emergency department for admitted patients (moderate recommendation; level III evidence) 5
- The minimum treatment duration is 5 days (level I evidence) 5
- The Infectious Diseases Society of America recommends switching from IV to oral therapy when patients are hemodynamically stable, clinically improving, able to take oral medications, and have normal GI function (strong recommendation; level II evidence) 5
Special Situations
- For suspected H5N1 infection, the Infectious Diseases Society of America recommends oseltamivir plus antibacterial agents targeting S. pneumoniae and S. aureus (level III evidence) 5